Circulating type 1 vaccine-derived poliovirus may evolve under the pressure of adenosine deaminases acting on RNA

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 28, Issue 17, 2015, Pages 2096-2099

  Liu, Yanhan ^a   Ma, Tengfei ^a   Liu, Jianzhu ^a   Zhao, Xiaona ^a   Cheng, Ziqiang ^a   Guo, Huijun ^a   Xu, Ruixue ^a   Wang, Shujing ^a  

^a SHANDONG AGRICULTURAL UNIVERSITY   (China)

Author keywords

ADARs; APOBECs; circulating type 1 vaccine; mutation; polio virus

Indexed keywords

ADENOSINE DEAMINASE; POLIOMYELITIS VACCINE; RNA; ORAL POLIOMYELITIS VACCINE; VIRUS RNA;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; HUMAN POLIOVIRUS 1; MUTATION RATE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA EDITING; VIRUS GENOME; VIRUS MUTATION; VIRUS STRAIN; VIRUS VIRULENCE; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTATION; PATHOGENICITY; POLIOMYELITIS VIRUS;

ADENOSINE DEAMINASE; BASE SEQUENCE; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; RNA, VIRAL;

EID: 84942794315     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2014.979147     Document Type: Article

References (31)

1. Hogle JM. Poliovirus cell entry: common structural themes in viral cell entry pathways. Ann Rev Microbiol 2002;56:677-702.
2. Sabin AB. Oral poliovirus vaccine. History of its development and prospects for eradication of poliomyelitis. JAMA 1965;194:872-6.
3. Salk JE, Krech U, Youngner JS, et al. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am J Public Health Nation's Health 1954;44:563-70.
4. Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Ann Rev Microbiol 2005;59:587-635.
5. Dunn G, Begg NT, Cammack N, Minor PD. Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J Med Virol 1990;32:92-5.
6. Minor PD, Macadam A, Cammack N, et al. Molecular biology and the control of viral vaccines. FEMS Microbiol Immunol 1990;2: 207-13.
7. Joce R, Wood D, Brown D, Begg N. Paralytic poliomyelitis in England and Wales, 1985-91. BMJ 1992;305:79-82.
8. Ogra PL, Faden HS, Abraham R, et al. Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis 1991;164:191-4.
9. Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002;296:356-9.
10. Bass BL. RNA editing by adenosine deaminases that act on RNA. Ann Rev Biochem 2002;71:817-46.
11. Nishikura K. Functions and regulation of RNA editing by ADAR deaminases. Ann Rev Biochem 2010;79:321-49.
12. Samuel CE. Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology 2011;411:180-93.
13. Chen CX, Cho DS, Wang Q, et al. A third member of the RNAspecific adenosine deaminase gene family, ADAR3, contains both single-and double-stranded RNA binding domains. RNA 2000;6: 755-67.
14. Gutierrez RA, Viari A, Godelle B, et al. Biased mutational pattern and quasispecies hypothesis in H5N1 virus. Infect Genet Evol 2013; 15:69-76.
15. Suspene R, Petit V, Puyraimond-Zemmour D, et al. Doublestranded RNA adenosine deaminase ADAR-1-induced hypermutated genomes among inactivated seasonal influenza and live attenuated measles virus vaccines. J Virol 2011;85: 2458-62.
16. Zahn RC, Schelp I, Utermohlen O, von Laer D. A-to-G hypermutation in the genome of lymphocytic choriomeningitis virus. J Virol 2007;81:457-64.
17. Suspene R, Renard M, Henry M, et al. Inversing the natural hydrogen bonding rule to selectively amplify GC-rich ADARedited RNAs. Nucleic Acids Res 2008;36:e72.
18. Ko NL, Birlouez E, Wain-Hobson S, et al. Hyperediting of human T-cell leukemia virus type 2 and simian T-cell leukemia virus type 3 by the dsRNA adenosine deaminase ADAR-1. J Gen Virol 2012; 93:2646-51.
19. Ebert D. Experimental evolution of parasites. Science 1998;282: 1432-5.
20. Hilleman MR. Vaccines in historic evolution and perspective: A narrative of vaccine discoveries. J Human Virol 2000;3:63-76.
21. Pathak VK, Temin HM. Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations. Proc Natl Acad Sci USA 1990; 87:6019-23.
22. Martinez MA, Vartanian JP, Wain-Hobson S. Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc Natl Acad Sci USA 1994;91:11787-91.
23. Vartanian JP, Meyerhans A, Sala M, Wain-Hobson S. G-4A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc Natl Acad Sci USA 1994;91:3092-6.
24. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003;300: 1112.
25. Mangeat B, Turelli P, Caron G, et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003;424:99-103.
26. Zhang H, Yang B, Pomerantz RJ, et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003;424:94-8.
27. Navaratnam N, Patel D, Shah RR, et al. An additional editing site is present in apolipoprotein B mRNA. Nucleic Acids Res 1991;19: 1741-4.
28. Bass BL, Weintraub H. A developmentally regulated activity that unwinds RNA duplexes. Cell 1987;48:607-13.
29. Rebagliati MR, Melton DA. Antisense RNA injections in fertilized frog eggs reveal an RNA duplex unwinding activity. Cell 1987;48: 599-605.
30. Toth AM, Zhang P, Das S, et al. Interferon action and the doublestranded RNA-dependent enzymes ADAR1 adenosine deaminase and PKR protein kinase. Prog Nucleic Acid Res Mol Biol 2006;81: 369-434.
31. Polson AG, Bass BL. Preferential selection of adenosines for modification by double-stranded RNA adenosine deaminase. EMBO J 1994;13:5701-11.